Agree.
Interesting the independent panel found no substantial evidence of effectiveness. Based on the observed slowing of the disease. It's also similar to the other drug that was being discussed which seemed to show slowing of the disease, yet FDA did not support it.
I hope this is not a concern for MPL going forward. Of course, that is pre-empting a phase 2 study but sounds like we have to jump over some higher bars to be worthy of FDA approval, not just an association with extended survival rates.
Another one that would be good to hear our CEO's thoughts on.
It seems Relyvrio will be a success regardless of the independent panels views.
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-143
-
- There are more pages in this discussion • 288 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $82.65M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.8¢ | $151.1K | 877.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 54714 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 371375 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |